key: cord-1001057-ojsdgxkl
authors: Vandercam, G.; Simon, A.; Scohy, A.; Belkhir, L.; Kabamba, B.; Rodriguez.Villalobos, H.; Yombi, J.C.
title: Clinical characteristics and humoral immune response in Healthcare Workers with COVID-19 in a Teaching Hospital in Belgium
date: 2020-09-18
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2020.09.018
sha: e421194b230d5a0a59ea097587a76da65e3e0b3b
doc_id: 1001057
cord_uid: ojsdgxkl

BACKGROUND: Healthcare workers (HCWs) are at high risk of acquiring COVID-19 and could play a role in nosocomial transmission. Since February 4, 2020, Belgian Health authorities reported more than 90568 cases, of which 8.3% were HCWs. Data on clinical characteristics, sources of infection and humoral immune response of HCWs with COVID-19 remain scarce. AIM: Analyse the clinical characteristics, humoral immune response, sources of contamination, and outcomes among HCWs with COVID-19. METHODS: This retrospective study includes 176 HCWs with laboratory-confirmed COVID-19 in a teaching hospital in Belgium. Between March 1(st), and May 31(th) 2020, all HCWs with symptoms suspect of COVID-19 were tested through a RT-PCR on a nasopharyngeal swab. Serological testing was performed between 55 and 137 days after the onset of symptoms. FINDINGS: Median age was 40.8 years and 75% were female. Median delay between onset of symptoms and diagnosis was 4.39 days. Most frequent symptoms were cough and headache (75% respectively). Fever accounted for 68.7%. Most represented professions were nurses (42%). HCWs were mainly infected by patient contact (32.9%). 7.6% required hospitalization and 1.7% were admitted in intensive care unit. Unfortunately, one HCW died (0.5 %). Total antibodies were positive in 109/126 (86.5%). CONCLUSIONS: Clinical presentation of COVID-19 in HCWs does not differ from the general population. However outcomes were more favourable with a mortality rate lower than that reported in Belgian COVID-19 patients in general (16%). The main source of infection was the hospital settings. Our positive antibodies rate was high but lower than what was reported.

In December 2019, a new coronavirus responsible for severe acute respiratory syndrome (SARS-CoV-2) appears in Wuhan, China [1] . The disease named later COVID-19 has now spread worldwide. The World Health Organisations (WHO) declared a pandemic the 11th of March 2020 [2] . Healthcare workers (HCWs) are at increased risk of being exposed to SARS- deaths worldwide. This also suggests that for every hundred HCWs who were infected, one died. At the end of August, more than 800 000 deaths had been recorded worldwide .The first case of SARS-CoV-2 infection in Belgium was reported on February 4, 2020. Since then, the Institute of Public Health in Belgium (Sciensano) has reported over 90 568 cases, of which 8.3% were HCWs [5] . Recently it was estimated that 600 HCWs had been hospitalized in Belgium due to the novel Coronavirus (COVID-19) since mid-March [5] . However, data on the clinical characteristics, outcomes, sources of infection, and humoral immune response of HCWs with COVID-19 infection remain scarce. We report here those factors amongst a cohort of 176 HCWs with laboratory confirmed COVID-19 in a large teaching hospital in Brussels, Belgium.

This was a retrospective study performed between March 1st, and May 31th, 2020, in a large teaching hospital (7757 employees), Cliniques Universitaires Saint-Luc (CUSL) in Brussels, Belgium. Ethical approval for this study (Ethical Committee N° CEHF 2020/06AVR/201) was provided by the IRB (CEBH of the Universite ćatholique de Louvain (UCLouvain), Brussels, Belgium), that provided a waiver for written informed consent, given the retrospective nature of the study, de-identified and anonymous analysis.

J o u r n a l P r e -p r o o f Demographic and clinical characteristics, RT-PCR and serological results were recorded using our institutional database (Medical Explorer 5v8) and the laboratory database. A standardized survey (written, sometimes completed by an oral interview) were use to collected other data such as the date of onset of symptoms, working places of the HCW, and plausible sources of contamination.

All employees of our hospital with symptoms suspect of COVID-19 were screened. Suspect symptoms were defined as fever, cough, shortness of breath or dyspnea, sore throat, rhinorrhoea, headaches, fatigue, myalgia, anosmia, ageusia, diarrhoea or other gastrointestinal symptoms. Two periods of screening were identified. The first was between March 1st and March 30th, when the Belgian Institute of Public Health (Sciensano) recommended screening HCWs if they had fever together with symptoms suspect of COVID-19; the second period was between April 1st, and May 31th when it was recommended to screen HCWs if they had symptoms suspect of COVID-19 irrespective of fever. Out of the 7757 hospital employees, 643 (8.3%) were screened. Among these 643 HCWs, 183 tested positive (28.5%) for SARS-CoV-2 by RT-PCR and 176 of them were included in this study (missing data). Some staff members (n=23) were also tested without criteria if they reported close contact with a confirmed SARS-COV-2 positive person. It is important to note that different measures were taken during that period of testing. The Belgian Government declared a partial lockdown on March 13 th (catering sector) which became full the 18 th of March (all non-essential shops).

Furthermore, masks were made mandatory for every hospital employee and patient from April 1 st , 2020 in our hospital (also the date when fever ceased to be a screening criterion). 

We classified the source of infection as coming from a patient (contact with a SARS-CoV-2 positive patient), a co-worker (SARS-COV-2 positive) or private (household member or private setting in whom a positive SARS-CoV-2 positive person was detected).The health J o u r n a l P r e -p r o o f care setting was then either patient or co-worker contact. To establish the source of infection, we asked HCW if they thought they had had contact with a patient, co-worker or an individual outside the healthcare setting who had been confirmed COVID-19 positive during the 14 days before symptom onset. If there was more than one possible contact we considered that the source was multiple; if there was no history of definite contact the source was deemed unknown. HCWs were considered in three groups: the first was HCWs working in COVIDdedicated wards; the second group was HCWs working in non-COVID wards; the final group was HCWs working in other hospital departments.

Serological testing was performed between June, 20th and June 30th, 2020 (55 and 137 days after the onset of symptoms on 126/176 HCWS (71.6%) in whom 79.3 % (100/126) was performed beyond 90 days. To investigate the humoral immune response, two methods were used. The first was the Roche Elecsys Anti SARS-CoV-2, which is a pan-immunoglobulin test targeting nucleocapsid with a reported sensitivity of 100% and specificity of 95% [6] . We considered a positive antibody response in HCW as a HCW with positive serology result on the Roche Elecsys Anti SARS-CoV-2. If this test was positive, a second test, the Maglumi™2019-n-Cov, was then performed to identify IgM or IgG antibodies (Snibe Diagnostic, Shenzhen, China). These are fully automated quantitative chemiluminescent immunoassays (CLIA) using magnetic microbeads coated with SARS-CoV-2 recombinant antigen labelled with ABEI, a non-enzyme small molecule with a special molecular formula that enhances stability in acid and alkaline solutions. The thresholds of positivity for these automated immunoassays are 1.0 AU/mL for IgM and IgG. The sensitivity and specificity are reported to be 64.5% and 100%, respectively [7] . Of note, diagnostic sensitivity is said to increase over time, reaching 95.5% (95% CI = 84.9-99.2) between 15 and 25 days after symptom onset [7] .

We collected data on an Excel sheet. We used GraphPad Prism version8 to performed analysis. Continuous variables were expressed as means with standard deviations and categorical variables were expressed as counts and percentages. Categorical variables were analyzed using chi-squared test or Fisher's exact test. Differences between means or medians were compared using unpaired Student's t-test or Mann-Whitney U test, according to the distribution. All tests were two-sided, with significance set at the 0.05 probability level J o u r n a l P r e -p r o o f summarizes their demographic and clinical characteristics. The median age of the HCWs was 40.8 years (24-64) and 75% were female. Median delay between symptom onset and diagnosis was 4.39 days (range 0-18).

The most frequent symptoms were cough and headache (both 75%), followed by sore throat/rhinorrhoea (71.5%). Fever, myalgia, and fatigue accounted for 68.7%, 65.3%, and 52.8% respectively. Other symptoms were shortness of breath (37.5%), gastro-intestinal symptoms, mostly diarrhoea (30.6%), and ageusia/anosmia (22.7%).

Among the 176 cases 30.1% worked in a COVID-dedicated ward, 46% worked in non-COVID ward and 23.8% in other departments ( Table 1 ). The most represented professions were nurses (42%) followed by non-paramedic workers (29.5%); physicians and paramedics accounted for 16.4% and 11.9% respectively. One priest was considered a paramedic as he had close contact with patients. Ageusia and or anosmia were the most predictive symptoms for positive antibodies, with.

28/29 HCWs with these symptoms being positive for total antibodies.

We describe here the clinical characteristics and humoral immune response, as well as sources of infection and outcomes in a cohort of HCWs with laboratory confirmed COVID-19 in our teaching hospital. The clinical presentation was quite similar to other recent studies [8] [9] [10] .

The United States Department of Health and Human Services (DHHS) reported a study of 4707 HCWs in whom 78% of the HCWs had cough, 68% fever, 66% myalgia, 65% headache, 50% sore throat/rhinorrhea, 41% shortness of breath, 32% diarrhea, and 16% loss of ageusia or anosmia [8] . These findings are in line with Chinese (110 HCWs) and Dutch (86 HCWs) studies [9] [10] . Symptoms in HCWs do not differ with those seen in the general population;, according to a meta-analysis by Hu et al, fever, cough, fatigue, dyspnea were present in 85.6%, 65.7%, 42.4%, and 21.4 % respectively [11] . In our series sore throat/rhinorrhea and headache was more common than in others series (71% and 75% respectively).

Regarding the source of infection, HCWs in our study were mainly infected through patient contact (32.9%). Private and co-worker contact accounted for 26.7% and 22.7% respectively.

Overall, 55.6% of infections were attributed to contact in health care settings, and HCWs working in a COVID unit were at greater risk (P< 0.0001). Likewise, Burrer et al. [8] found that exposure in a health care setting accounted for 55% of the cases, household setting 27%, community setting 13% and multiple exposure settings 5%. Lai et al [9] in a study of 110

Chinese HCWs with COVID-19 reported that 65 (59.1%) infections were attributed to contact with patients, 12 (10.9%) to contact with colleagues, and 14 (12.7%) to contact with family or friends.

In our study HCWs from COVID dedicated ward were mainly infected by patient contact (66%) while contamination by a co-worker was the principal source of infection for HCWs from other departments of the hospital (42.8%). For the HCWs from non-COVID wards, private sphere seems to be the first source of contamination (30.8%), with contamination by patient contact coming second (27.1%). In a recent meta-analysis [12] , data on the specialty of HCWs and the area of the hospital where they were exposed were not available in most of the studies. Only Wang et al. [13] had reported that among the affected HCWs, 77.5% worked on general wards, 17.5% in the emergency department and 5% in the intensive care unit. It is important to note that some HCWs worked in both COVID-dedicated ward and non-COVID ward. Indeed, McMichael et al. [14] had described the incidence of COVID-19 among HCWs working in long-term care facilities, and showed that the temporal and geographical transmission of the disease was in part due to the movement of HCWs from one facility to another.

The outcome of COVID-19 was good, as many of the HCWs presented with mild disease. 13 over 176 patients required hospitalizations (7.4%) of whom six had severe, and three critical, illness. The median age of hospitalized HCWs was 12 years higher than those who were not hospitalized, and all but one had comorbidities. The mortality in our cohort was lower than reported in COVID-19 patients in general in Belgium (16%) [5] . Sahu et al [12] analyzed the incidence of severe or critical disease and deaths among the affected HCWs. The incidence of severe or critical disease was nearly three times lower compared with all positive COVID-19 patients (9.9% vs 29.4%), and the mortality among HCWs was seven times lower (0.3% vs 2.3%). These observations may be explained by the younger age of HCW, who are also less likely to have comorbidities [14] . Indeed, the median age of HCWs with COVID-19 was 52 J o u r n a l P r e -p r o o f years compared to 71 years in all COVID-19 hospitalized patients in Belgium [5] . A US study showed only 6% of HCWs were aged >65 years but 37% of the deaths occurred among this age group [8] . The one HCW who died in our series was aged of 51 years and had chronic neutropenia.

Concerning humoral immune response, total antibodies were positive in 109/126 (86.5%) of HCWs and on the 109 total antibodies positive: 69/109 (63.3 %) were IgG positive. A large study in Spain [15] reported a seroprevalence close to 90% after 14 days since a positive PCR test, which is consistent with a recent study concluding that SARS-CoV-2 IgG antibodies are detected in more than 90% of infected people two weeks after symptom onset [16] and the recently reported 99% of antibody response among confirmed COVID-19 cases [17] . Our results seem to be lower than those reported by other authors [15] [16] [17] . This can be partially explained by the fact that we performed serological testing in the majority of time more than three months after the onset of symptoms (80%). Indeed, rapid decrease of anti-SARS-CoV-2 antibodies in persons with mild Covid-19 have been described [18] [19] . Long March, 1 st and the days after May, 18 th were hidden from the graph to ensure a better visibility (no tests were performed on HCWs during these periods). Arrow represents the date (April, 4 th ) when universal masking was made mandatory inside the hospital. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

WHO Director-General's opening remarks at the media briefing on COVID19 -March 3. International Council of Nurses

Infection and mortality of healthcare workers worldwide from COVID-19: a scoping review

Epidemiological situation of the coronavirus in Belgium: daily report of national and international situation

Full specifications of Roche's Elecsys® Anti-SARS-CoV-2 antibody test and immunoassay systems, including throughput, can be found on our diagnostics

Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients

Characteristics of Health Care Personnel with COVID-19 -United States

Coronavirus Disease 2019 (COVID-2019) Infection Among Health Care Workers and Implications for Prevention Measures in a Tertiary Hospital in Wuhan, China

Prevalence and Clinical Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During an Early Phase of the Pandemic

Prevalence and Severity of Corona Virus Disease 2019 (COVID-19): a Systematic Review and Metaanalysis

COVID-19 in healthcare workers-A systematic review and meta-analysis

Epub ahead of print

Epidemiology of Covid-19 in a Long-Term Care Facility in King County

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, populationbased seroepidemiological study

Evidence summary of the immune response following infection with SARS-CoV-2 or other human coronaviruses

Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Spread of SARS-CoV-2 in the Icelandic Population